Clinical Laboratory of China Meitan General Hospital

Beijing, China

Clinical Laboratory of China Meitan General Hospital

Beijing, China
SEARCH FILTERS
Time filter
Source Type

Zhong L.,Peking University | Li Y.,Capital Medical University | Tian H.,Peking University | Guo L.,Clinical Laboratory of China Meitan General Hospital | And 2 more authors.
International Journal of Clinical and Experimental Pathology | Year: 2017

Tuberculosis (TB) is a severe infectious disease caused by mycobacterium tuberculosis. Early and reliable diagnosis of this disease is very important. In this study, proteomic profiling analysis was performed for serum samples from TB patients and healthy controls. The samples were analyzed by data-independent acquisition mass spectrometry coupled with high performance liquid chromatography (HPLC-DIA-MS) to identify candidate serum biomarkers that could provide clues for TB diagnosis. A total of 647 serum proteins were identified using DIA acquisition strategy, and statistical analysis showed that 88 proteins were significantly dysregulated between TB and control groups. Furthermore, bioinformatic analysis was used to reveal TB relevant pathways and regulative networks for pathology study. As a result, a protein-protein interaction network was constructed to reveal the relationship between the 88 dysregulated proteins, and the pathway of complement and coagulation cascades and ECM-receptor interaction were significantly relevant to TB disease state. Finally, to further assess the validity of these findings, LRG1 was selected for subsequent ELISA assays, and the ELISA result validated the reliability of this proteomic analysis. In summary, our findings reveal several potential serum biomarkers for TB diagnosis, and the results of proteomic and bioinformatic analysis can also provide valuable information for TB pathology studies.


Zheng Z.,Peking Union Medical College | Zheng M.,Hebei United University | Bi J.,Peking Union Medical College | Feng Q.,Peking Union Medical College | And 5 more authors.
International Journal of Clinical and Experimental Medicine | Year: 2015

Objective: This study aimed to confirm the potential of growth-related gene product β (GROβ) as a biomark-er for colorectal cancer. We compared serum GROβ levels in patients with colorectal cancer, healthy individuals and individuals with non-tumor diseases. Methods: We measured serum GROβ levels with enzyme-linked immunosor-bent assay in patients with colorectal cancer (123 preoperative samples and 66 postoperative samples), 88 healthy controls and 125 individuals with other diseases. Serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) were measured in all samples with an immunoluminometric assay. Statistical analyses were performed to determine associations between serum GROβ levels and clinical parameters for colorectal cancer. A receiver operating characteristic (ROC) curve was analyzed for GROβ, CEA and CA19-9. Results: The serum GROβ levels were much higher in patients with colorectal cancer (median: 96.15 pg/ml) than those in healthy controls (median: 43.28 pg/ml, P < 0.01) and other disease controls (median: 57.30 pg/ml, P < 0.01). Serum GROβ levels in colorectal cancer were correlated positively with tumor-node-metastasis staging (P < 0.01) and the depth of infiltration (P < 0.05), but not with the histological grade, tumor embolus, lymph node metastasis, gross pathologic tumor type, or patient gender. The sensitivity and specificity of the assay for serum GROβ were 56.1% (69/123) and 95.31% (203/213), respectively. The area under the ROC curve constructed with GROβ (0.834) was larger than that constructed with CEA (0.739) or CA19-9 (0.676) for discriminating colorectal cancer from matched controls. Conclusion: These preliminary results suggested that the serum GROβ level could be a useful biomarker for colorectal cancer diagnoses. © 2015, Int J Clin Exp Med. All Rights Reserved.


Gao H.,Clinical Laboratory of China Meitan General Hospital | Zheng Z.,Peking Union Medical College | Mao Y.,Peking Union Medical College | Wang W.,Chinese PLA General Hospital | And 6 more authors.
Cancer Letters | Year: 2014

Our aim was to identify novel tumor-associated antigens from the esophageal squamous cell carcinoma (ESCC) cell line EC0156, and related autoantibodies in sera from patients with ESCC. We used modified serological proteome analysis, involving one- and two-dimensional electrophoresis, Western blot, and MALDI-TOF/TOF-MS to identify 6 ESCC-associated antigens. From these, 105. kDa heat shock protein (HSP105) and triosephosphate isomerase (TIM) were further evaluated and we determined they could induce autoantibody responses in ESCC sera and are highly expressed in ESCC tissues. Anti-HSP105 and anti-TIM autoantibodies were found in 39.1% (18/46) and 34.8% (16/46) of patients with ESCC, respectively, but only in two controls. A receiver operating characteristic curve constructed with HSP105 and TIM gave a sensitivity of 54.3% and 95% (38/40) specificity in discriminating ESCC from matched controls. Interestingly, we found that autoantibodies against TIM in ESCC serum mainly reacted with glycosylated but not deglycosylated TIM. The preliminary results suggest the potential utility of screening autoantibodies in sera for use as biomarkers for cancer diagnosis. © 2013 Elsevier Ireland Ltd.

Loading Clinical Laboratory of China Meitan General Hospital collaborators
Loading Clinical Laboratory of China Meitan General Hospital collaborators